Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Eterna Therapeutics ( (ERNA) ) has provided an update.
Eterna Therapeutics Inc. has faced a compliance issue with the Nasdaq Stock Market due to its market value of listed securities falling below the required $35 million for 35 consecutive business days, triggering a notice from Nasdaq. The company now has a 180-day period to regain compliance, or it risks delisting, although its stock will continue to trade under the symbol ‘ERNA’ for now. Additionally, Dorothy Clarke has resigned from the Board of Directors but remains as general counsel, and Dr. Elena Ratner has been appointed as a new independent director, effective January 7, 2025.
More about Eterna Therapeutics
YTD Price Performance: -12.70%
Average Trading Volume: 878,325
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $16.61M
See more insights into ERNA stock on TipRanks’ Stock Analysis page.
